Back to search

Article

Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

2019-12-19

Abstract excerpt

<h4>Background: </h4> This retrospective study evaluates the survival effects of metronomic maintenance therapy with fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. <h4>Methods:</h4> We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological fea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
33676aae-ee8d-58da-bf4b-3fa90b76d02b
DOI
10.20944/preprints201912.0246.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based ChemotherapyDOI 10.20944/preprints201912.0246.v1
The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential PredictorSemantic proximity
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.Semantic proximity
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status.Semantic proximity
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10Semantic proximity
[Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage II( and III( colorectal cancer].Semantic proximity
Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.Semantic proximity
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.Semantic proximity
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.Semantic proximity
[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].Semantic proximity
REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.Semantic proximity
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.Semantic proximity
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.Semantic proximity
Select a neighboring publication to make it the new centre.